The application of transgenic mice for therapeutic antibody discovery.
In 2006, panitumumab, the first fully human antibody generated from transgenic mice, was approved for clinical use by the US Food and Drug Administration (FDA). Since then, a further seven such antibodies have been approved. In this chapter, we discuss how transgenic mice technologies can provide a powerful platform for creating human therapeutic antibodies.
Kymab Ltd, Meditrina, Cambridge, UK. E-Chiang.Lee@kymab.com
E-Chiang
EC
Lee
Michael
M
Owen
D000818:Animals; D000906:Antibodies / Q000235:genetics / Q000378:metabolism* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000235:genetics / Q000378:metabolism* / Q000627:therapeutic use; D006801:Humans; D007136:Immunoglobulins / Q000235:genetics / Q000378:metabolism / Q000627:therapeutic use; D051379:Mice; D008822:Mice, Transgenic; D019151:Peptide Library
D000906:Antibodies; D061067:Antibodies, Monoclonal, Humanized; D007136:Immunoglobulins; D019151:Peptide Library